PFIZER INC.
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A 52-Week Multicenter Study Evaluating the Safety and Efficacy of Varenicline for the Maintenance of Smoking Cessation
Phase 3
Completed
- Conditions
- Smoking Cessation
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2007-06-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 2000
- Registration Number
- NCT00143286
- Locations
- π¬π§
Pfizer Investigational Site, London, United Kingdom
An Open Label Study That Compares Varenicline to Transdermal Nicotine Patch for Smoking Cessation
Phase 3
Completed
- Conditions
- Smoking Cessation
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2007-06-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 730
- Registration Number
- NCT00143325
- Locations
- π¬π§
Pfizer Investigational Site, Nottingham, United Kingdom
Assessment of Efficacy and Safety of UK-390,957 in Men With Premature Ejaculation
Phase 2
Completed
- Conditions
- Ejaculation
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2012-11-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 460
- Registration Number
- NCT00143117
- Locations
- πΊπΈ
Pfizer Investigational Site, Milwaukee, Wisconsin, United States
To Examine the Lung When People With Diabetes Take an Inhaled Form of Insulin, Compared to Subcutaneous Insulin.
Phase 2
Completed
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2008-02-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 20
- Registration Number
- NCT00143338
- Locations
- πΊπΈ
Pfizer Investigational Site, San Antonio, Texas, United States
Pregabalin Open-Label Extension Trial in Patients With Partial Seizures
Phase 3
Completed
- Conditions
- Epilepsies, PartialEpilepsy, Complex Partial
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2006-07-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 300
- Registration Number
- NCT00143143
- Locations
Pfizer Investigational Site
Morphine-Sparing Effect And Safety Of Parecoxib Administered Intravenously For The Treatment Of Postoperative Pain
Phase 3
Completed
- Conditions
- Pain, Postoperative
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2008-04-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 220
- Registration Number
- NCT00143169
- Locations
- π¨π³
Pfizer Investigational Site, Shanghai, China
Multicentre Trial to Evaluate the Safety and Efficacy of CP-316,311 in Major Depressive Disorder
Phase 2
Terminated
- Conditions
- Depressive Disorder, Major
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2008-03-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 200
- Registration Number
- NCT00143091
- Locations
- π·πΊ
Pfizer Investigational Site, St.-Petersburg, Russian Federation
A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2016-01-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 74
- Registration Number
- NCT00141297
- Locations
- πΊπΈ
Karmanos Cancer Institute, Detroit, Michigan, United States
πΊπΈMemorial Sloan Kettering Cancer Center, New York, New York, United States
πΊπΈAbramson Cancer Center Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Evaluation Of A Novel Methodology In The Assessment Of Urethral Function Using SS-RBX.
Phase 2
Completed
- Conditions
- Urinary Incontinence, Stress
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2011-06-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 18
- Registration Number
- NCT00141128
- Locations
- π©π°
Pfizer Investigational Site, Glostrup, Denmark
To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures
Phase 3
Completed
- Conditions
- Seizure Disorder, Partial
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2009-11-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 455
- Registration Number
- NCT00141388
- Locations
- π¨π¦
Pfizer Investigational Site, Montreal, Quebec, Canada
Β© Copyright 2025. All Rights Reserved by MedPath